The role of hormonal, metabolic and inflammatory biomarkers on sleep and appetite in drug free patients with major depression: A systematic review.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 05 2019
Historique:
received: 06 12 2018
revised: 30 01 2019
accepted: 03 03 2019
pubmed: 15 3 2019
medline: 30 6 2019
entrez: 15 3 2019
Statut: ppublish

Résumé

Major depressive disorder (MDD) is a complex and heterogeneous disorder in which clinical symptoms can widely differ among patients. Neurovegetative symptoms, i.e. decreased or increased appetite, changes in body weight and sleep disturbances, described as 'melancholic' or 'atypical' features of a depressive episode, are the most variable symptoms among patients with MDD. We hypothesized biomarkers differences underlying this neurovegetative variability in major depression. We systematically reviewed, according to the PRISMA guidelines, the role of specific metabolic, hormonal and inflammatory biomarkers in drug-free MDD patients, that could have neurobiological effects on appetite, weight regulation and circadian rhythms, influencing eating behaviour and sleep patterns. All studies regarding the co-occurrence of disturbed sleep and appetite were examined. Besides the well-known leptin and ghrelin, other biomarkers such as BDNF, VEGF, NPY, orexin, and the recent discovered nesfatin-1 seem to be involved in neurovegetative changes in depressive disorders playing a role in the regulation of affective states, stress reactions and sleep patterns. Interestingly, based on the existing evidence, ghrelin, orexin and nesfatin-1 could be linked both to sleep and appetite regulation in depressed patients. Heterogeneous studies with low sample size. Despite the wide heterogeneity of results, studies on biomarkers of appetite and sleep in MDD are an interesting field of research to explain the neurobiological substrates of depressive symptoms that deserve further investigation.

Sections du résumé

BACKGROUND
Major depressive disorder (MDD) is a complex and heterogeneous disorder in which clinical symptoms can widely differ among patients. Neurovegetative symptoms, i.e. decreased or increased appetite, changes in body weight and sleep disturbances, described as 'melancholic' or 'atypical' features of a depressive episode, are the most variable symptoms among patients with MDD. We hypothesized biomarkers differences underlying this neurovegetative variability in major depression.
METHODS
We systematically reviewed, according to the PRISMA guidelines, the role of specific metabolic, hormonal and inflammatory biomarkers in drug-free MDD patients, that could have neurobiological effects on appetite, weight regulation and circadian rhythms, influencing eating behaviour and sleep patterns. All studies regarding the co-occurrence of disturbed sleep and appetite were examined.
RESULTS
Besides the well-known leptin and ghrelin, other biomarkers such as BDNF, VEGF, NPY, orexin, and the recent discovered nesfatin-1 seem to be involved in neurovegetative changes in depressive disorders playing a role in the regulation of affective states, stress reactions and sleep patterns. Interestingly, based on the existing evidence, ghrelin, orexin and nesfatin-1 could be linked both to sleep and appetite regulation in depressed patients.
LIMITATIONS
Heterogeneous studies with low sample size.
CONCLUSIONS
Despite the wide heterogeneity of results, studies on biomarkers of appetite and sleep in MDD are an interesting field of research to explain the neurobiological substrates of depressive symptoms that deserve further investigation.

Identifiants

pubmed: 30870775
pii: S0165-0327(18)33084-2
doi: 10.1016/j.jad.2019.03.015
pii:
doi:

Substances chimiques

Biomarkers 0
Hormones 0
Inflammation Mediators 0

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

249-259

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Mariarita Caroleo (M)

Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

Elvira Anna Carbone (EA)

Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

Amedeo Primerano (A)

Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

Daniela Foti (D)

Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

Antonio Brunetti (A)

Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

Cristina Segura-Garcia (C)

Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy. Electronic address: segura@unicz.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH